甘李药业股份有限公司

北京市

Years

李芷莹

查看

基本信息

企业名称

甘李药业股份有限公司

企业地址

北京市通州区漷县镇南凤西一路8号

成立日期

1998

企业规模（人）

500以上

年销售额（USD）

不愿意公开

企业简介

Founded in 1998, Gan & Lee Pharmaceuticals is a leading biopharmaceutical company in China specializing in the development, production, and commercialization of insulin analogs and supporting medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters and nearly 3000 employees. With state-of-the-art buildings and GMP facilities, Gan & Lee has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment.

主要竞争优势

品牌,国际认证/标准,经验丰富的研发人员,生产能力,合同定制,良好的信誉,优质服务

邮政编码

101109

里程碑

1998 - Developed China’s first recombinant human insulin 2001 - Developed China's first fast-acting insulin analog (lispro) 2002 - Developed China’s first long-acting insulin analog (glargine) and first premixed insulin analog (lispro 25) 2009 - Developed China’s first insulin pen 2013 - Developed second generation insulin pen 2014 - Founded US subsidiary - Gan & Lee Pharmaceuticals USA 2015 - Initiated phase I clinical trial on insulin glargine in Germany 2017 - Initiated phase III clinical trials on insulin glargine in the USA and EU 2019 - Initiated phase I clinical trials on insulin lispro and aspart in the USA and EU 2020 - Initially listed on the A-share index on the Shanghai Stock Exchange 2021 - Completed phase I clinical trials on insulin glargine in Germany

贸易信息

业务类型

制造商,出口商

主要销售市场

北美洲,中/南美洲,西欧,东欧,亚洲,中东,非洲

主营产品类别

药品制剂,生物制品,原料药